Parnell Acquires Noble Pharma

DW Healthcare Partners Invests in Vets Plus and Noble Pharma

January 10, 2022

Veterinary

DW Healthcare Partners completed a growth capital investment in Vets Plus, Inc. and Noble Pharma, LLC, backing the animal-health manufacturer to scale operations and expand pharmaceutical capabilities. As part of the transaction, Dave Nelson becomes President and CEO of Vets Plus while founder Raj Lall transitions from day-to-day management and remains on the board.

RCBC BidCo Pty Ltd Extends Offer to Acquire Parnell Pharmaceuticals Holdings Ltd

January 31, 2025

Pharmaceuticals

RCBC BidCo Pty Ltd announced an extension of its offer (dated November 29, 2024) to acquire up to 100% of the ordinary shares of Parnell Pharmaceuticals Holdings Ltd from existing shareholders. The offer expiration was extended to 5:00pm Friday, March 14, 2025 (New York City time), with completion now expected on or before Wednesday, March 19, 2025.

Olympus Partners Acquires PAI Pharma

February 24, 2025

Pharmaceuticals

Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.

Knight Therapeutics Acquires Endo's International Pharmaceuticals Business (Paladin Pharma)

June 17, 2025

Pharmaceuticals

Knight Therapeutics has completed the acquisition of Endo's International Pharmaceuticals business, primarily operated through Canada-based Paladin Pharma Inc. The divestiture closed for up to approximately $105 million in cash (about $79 million at closing, ~$11 million in permitted holdbacks and up to $15 million contingent on milestones).

Parabellum Investments Acquires Advanco

September 24, 2023

Software

London-based private equity firm Parabellum Investments acquired Advanco, a Belgian pharma serialization and track-and-trace software specialist. Advanco — maker of the ARC Level‑3 site-management serialization platform — will pursue organic growth and M&A and is partnering with Syntegon on new or revamped serialization projects globally.

APNAR Pharma Acquires Aurex Laboratories

February 3, 2022

Pharmaceuticals

APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.